Evidence map›Paper›PMID 31447392›Full record

ArticleHPB : the official journal of the International Hepato Pancreato Biliary Association2020

Disease-free interval and tumor functional status can be used to select patients for resection/ablation of liver metastases from adrenocortical carcinoma: insights from a multi-institutional study.

Reed I Ayabe, Raja R Narayan, Samantha M Ruff, Michael M Wach, Winifred Lo, Pieter M H Nierop, Seth M Steinberg, R Taylor Ripley, Jeremy L Davis, Bas G Koerkamp and 4 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in HPB : the official journal of the International Hepato Pancreato Biliary Association, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Reed I AyabeSurgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Raja R NarayanHepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Samantha M RuffSurgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Michael M WachSurgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Winifred LoSurgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Pieter M H NieropDepartment of Surgery, Erasmus University Medical Centre, Rotterdam, Netherlands.
Seth M SteinbergBiostatistics and Data Management Section, Office of the Clinical Director, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
R Taylor RipleySurgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Jeremy L DavisSurgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Bas G KoerkampDepartment of Surgery, Erasmus University Medical Centre, Rotterdam, Netherlands.
Michael I D'AngelicaHepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
T Peter KinghamHepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
William R JarnaginHepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Jonathan M HernandezSurgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. Electronic address: jonathan.hernandez@nih.gov.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Office of Collaborative BiostatisticsZIDSC007202 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · PI CHOO-WOSOBA, HYOYOUNG · 2009 to 2025
$14.5M
Evaluating outcomes for patients with primary-metastatic gastrointestinal cancerZIABC011861 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI HERNANDEZ, JONATHAN · 2019 to 2025
$166k
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

backgroundAdrenocortical carcinoma (ACC) is an aggressive malignancy that frequently metastasizes to the liver. Given the limitations of systemic therapy in this setting, we sought to determine characteristics associated with a two-fold increase in survival with resection/ablation compared to that reported with chemotherapy alone (∼12 months).

methodsPatients who underwent resection/ablation at our institutions for ACC liver metastases were identified. Those who survived 12-24 months after metastasectomy were excluded, as the aim was to characterize patients who most clearly benefited from these procedures. Clinicopathologic and treatment characteristics were assessed for associations with survival.

resultsSixty-two patients met inclusion criteria, of whom 44 survived >24 months and 18 survived <12 months. Patients with extended survival were less likely to have functioning tumors (p = 0.047), had fewer liver metastases (p = 0.047), and a longer disease-free interval (DFI) (median 17.6 vs 2.3 months, p < 0.0001). On multivariable analysis, DFI (OR = 1.33, 95% CI = 1.12-1.58) and non-functioning tumor (OR = 0.13, 95% CI = 0.13-0.56) were independently associated with prolonged survival.

conclusionMetastasectomy/ablation should be considered for patients with ACC liver metastases. DFI and tumor functional status may be useful in selecting optimal candidates for these procedures.

Indexed as

MetastasectomyAdrenal Cortex NeoplasmsAdrenocortical CarcinomaAdultDisease-Free SurvivalFemaleHepatectomyHumansLiver NeoplasmsMaleMiddle AgedPatient SelectionRadiofrequency AblationRetrospective StudiesSurvival Rate

Identifiers

PMID31447392
PMCPMC7948253

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.